Innovative Medication Shows Promise in Managing Resistant Hypertension and Protecting Kidney Function
A new drug, baxdrostat, shows promise in effectively lowering resistant high blood pressure and protecting kidney health, offering hope for a significant advancement in hypertension and kidney disease treatment.
A groundbreaking medication, baxdrostat, has demonstrated significant potential in lowering blood pressure levels that are difficult to control with standard treatments and may also slow the progression of kidney disease. In a recent stage 2 clinical trial involving nearly 200 participants, baxdrostat not only led to a substantial reduction in blood pressure but also showed promising effects on kidney health. Participants treated with baxdrostat exhibited less than half the amount of urinary albumin—a key marker of kidney damage—compared to those receiving traditional care, indicating healthier kidneys.
The research, led by Dr. Jamie Dwyer at the University of Utah Health, highlights the dual benefits of the drug. On average, baxdrostat lowered blood pressure by approximately 8.1 mm Hg more than standard treatments. This is corroborated by a larger, almost 800-patient trial where similar blood pressure reductions were observed, establishing baxdrostat as a potential game-changer in hypertension management.
Unlike conventional medications, baxdrostat operates through a unique mechanism by reducing the production of aldosterone, a hormone that raises blood pressure by increasing salt retention and contributes to kidney inflammation and scarring. Up to a quarter of people with resistant high blood pressure have elevated aldosterone levels, making baxdrostat particularly effective for this demographic.
Given its ability to target the hormone source directly, baxdrostat offers hope not only for better blood pressure control but also for protecting kidney function, especially for the one in seven adults in the U.S. living with chronic kidney disease. Currently, phase III trials are underway to further verify its benefits. The promising results suggest that baxdrostat could revolutionize treatment strategies for resistant hypertension and kidney health, potentially transforming patient outcomes.
Source: https://medicalxpress.com/news/2025-09-drug-lowers-treatment-resistant-high.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Impact of Restricted Public Health Data on Flu Forecasting and Public Safety
Limiting access to vital public health data hampers influenza forecasting and disease response efforts. New research highlights the risks of data suppression for public safety and health decision-making.
Innovative In Vitro Model Sheds Light on How Tumor Cells Enter the Bloodstream
A cutting-edge in vitro model reveals the detailed mechanism by which tumor cell clusters penetrate blood vessel walls and facilitate metastasis, paving the way for new targeted therapies against cancer spread.
New State Scorecard Highlights Preparedness for Climate-Related Health Threats
A new report ranks U.S. states based on their preparedness to handle climate-related health risks, highlighting regional strengths and vulnerabilities. Learn which states are leading in resilience and which need urgent action.
